Corneal Refractive Surgery in Patients with History of Optic Neuritis
Purpose: The purpose of this study was to evaluate the risk of recurrence of optic neuritis after corneal refractive surgery in patients with a history of optic neuritis and to examine the safety and efficacy of the procedure in this population.
Methods: This was a retrospective chart review of patients with a history of optic neuritis who underwent laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK) at a single tertiary center from June 1996 to December 2014. Fifteen eyes of 14 patients were included in this study. Visual acuity before and after the surgery was recorded. Patients were followed-up for over five years postoperatively for the recurrence of optic neuritis.
Results: The average LogMAR best corrected visual acuity (BCVA) preoperatively was 0.12 ± 0.19 (–0.10 to 0.60) and postoperatively was 0.06 ± 0.10 (–0.10 to 0.30). No eyes lost lines of BCVA. The average LogMAR uncorrected distance visual acuity (UDVA) after surgery was 0.12 ± 0.13 (0.00 to 0.48). Twenty-eight percent of patients reached a UDVA of 20/20 or better after refractive surgery. Optic neuritis recurred in 3/15 (20%) eyes and 3/14 patients (21%).
Conclusion: While corneal refractive procedures appear safe in patients with a history of optic neuritis, our data suggest that their efficacy may be reduced.
Laser vision surgery, LASIK, Multiple sclerosis, Optic Neuritis, PRK
1. Hackett ER, Martinez RD, Larson PF, Paddison RM. Optic neuritis in systemic lupus erythematosus. Arch Neurol 1974;31:9–11.
2. Kadota Y, Tokumaru A, Kamakura K, Kohyama S, Okizuka H, Kaji T, et al. Primary Sjögren’s syndrome initially manifested by optic neuritis: MRI findings. Neuroradiology 2002;44:338–341.
3. Cikes N, Bosnic D, Sentic M. Non-MS autoimmune demyelination. Clin Neurol Neurosurg 2008;110:905–912.
4. Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978;86:648–655.
5. The clinical profile of optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 1991;109:1673– 1678.
6. Lightman S, McDonald WI, Bird AC, Francis DA, Hoskins A, Batchelor JR, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987;110:405–414.
7. Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye Res 2015;49:17–45.
8. Schallhorn JM, Schallhorn SC, Hettinger KA, Venter JA, Pelouskova M, Teenan D, et al. Outcomes and complications of excimer laser surgery in patients with collagen vascular and other immune-mediated inflammatory diseases. J Cataract Refract Surg 2016;42:1742–1752.
9. Moshirfar M, Siddharthan KS, Meyer JJ, Espandar L, Wolsey DH, Vitale AT. Risk for uveitis after laser in situ keratomileusis in patients positive for human leukocyte antigen-B27. J Cataract Refract Surg 2008;34:1110–1113.
10. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287–290.
11. Cameron BD, Saffra NA, Strominger MB. Laser in situ keratomileusis–induced optic neuropathy. Ophthalmology 2001;108:660–665.
12. Dotan S, Beykin G, Frucht-Pery J. Optic neuritis after refractive surgery: causal or coincidence? [cited July 10, 2018].
13. Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995;45:244–250.
14. Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol 2014;13:83–99.
15. de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol 2006;90:551–554.
16. Hashemi H, Tabrizi M, Rezvan B. Laser in situ keratomileusis for the treatment of refractive errors in patients with multiple sclerosis. Iran J Ophthalmol 2010;22:9–12.
17. Yang X-J, Yan H-T, Nakahori Y. Evaluation of the effectiveness of laser in situ keratomileusis and photorefractive keratectomy for myopia: a meta-analysis. J Med Invest 2003;501:80–186.
18. Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol (Chicago, Ill 1960) 2003;121:944–949.
19. Optic Neuritis Study Group TONS. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial followup. Arch Neurol 2008;65:727–732.
20. Pelli DG, Bex P. Measuring contrast sensitivity. Vision Res 2013;90:10–14.
21. Yamane N, Miyata K, Samejima T, Hiraoka T, Kiuchi T, Okamoto F, et al. Ocular higher-order aberrations and contrast sensitivity after conventional laser in situ keratomileusis. Invest Opthalmol Vis Sci 2004;45:3986.
22. Katlun T, Wiegand W. [Change in twilight vision and glare sensitivity after PRK]. Ophthalmologe 1998;95:420–426.